这项研究分析了植入物突出长度(IPL)对影响使用非移植骨凿窦底抬高(OSFE)同时植入的长期结果的可能因素的影响,并探索IPL的最佳范围。
采用回顾性研究设计。经过3-9年(平均5.04年)的随访,收集了65例患者的105个植入物的临床和影像学数据。IPL分为三组(组1,IPL<2mm;组2,2mm≤IPL<4mm;组3,IPL≥4mm)。窦内骨增益(ESBG),种植体周围边缘骨丢失(MBL),骨与种植体接触长度(BICL),和ESBG百分比(%ESBG)用于评估非接枝OSFE。进行Kaplan-Meier分析以评估累积生存率。采用多元线性回归模型探讨可能的影响因素与ESBG的关系。应用方差分析(ANOVA)探讨IPL与ESBG的相关性,MBL,BICL,和%ESBG。
62例患者共102个植入物符合生存标准,基于植入物的分析和基于患者的分析的累积生存率分别为96.4%和94.1%,分别。平均ESBG,MBL,最新随访时BICL为1.95±0.88毫米,0.58±0.68mm,5.51±1.47毫米。发现ESBG与IPL呈正相关。当IPL超过4mm时,发现骨形成效率显着降低(P=0.02)。
当应用非移植OSFE并同时放置植入物时,为了获得更好的长期结果,建议在4mm内的最佳IPL范围。
This study analyzed the influence of implant protrusion length (IPL) on the possible factors that affect the long-term outcomes utilizing non-grafting osteotome sinus floor elevation (OSFE) with simultaneous implant placement, and to explore the optimal range of IPL.
A retrospective study design was adopted. The clinical and radiographic data of 105 implants in 65 patients were collected after 3-9 (mean 5.04) years follow-up. IPL was divided into three groups (group1, IPL<2mm; group2, 2mm≤IPL<4mm; group3, IPL≥4mm). Endo-sinus bone gain (ESBG), peri-implant marginal bone loss (MBL), bone to implant contact length (BICL), and percentage of ESBG (%ESBG) were used to evaluate non-grafting OSFE. A Kaplan-Meier analysis was performed to assess the cumulative survival rate. Multiple linear regression model was used to explore the relationship between the possible influence factors and ESBG. Analysis of variance (ANOVA) was applied to explore the correlation of IPL with ESBG, MBL, BICL, and %ESBG.
A total of 102 implants in 62 patients fulfilled the survival criteria, giving the cumulative survival rates of 96.4% and 94.1% for implant-based analysis and patient-based analysis, respectively. The mean ESBG, MBL, and BICL at the latest follow-up were 1.95±0.88 mm, 0.58±0.68 mm, and 5.51±1.47 mm. ESBG was found to be positively correlated to IPL. A significant decreased bone formation efficiency was found when IPL was over 4 mm (P=0.02).
An optimal range of IPL within 4 mm was recommended for better long-term outcomes when applying non-grafting OSFE with simultaneous implant placement.